F.L. Putnam Investment Management’s Exagen XGN Stock Holding History

F.L. Putnam Investment Management’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.34M	Buy	+288,810	New	+$1.09M	0.02%	338

Other funds holding XGN

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GWN Securities Palm Beach Gardens, Florida $598M AUM 32.4% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

AXQ Capital Jersey City, New Jersey $920M AUM 18.71% 1-Year Est. Return

R Squared Central, Hong Kong $190M AUM 25.89% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

F.L. Putnam Investment Management's XGN Position: Q2 2026 in Review

F.L. Putnam Investment Management opened a new position in Exagen (XGN) in Q2 2026: 288,810 shares worth $1.34M. The stake represents 0.02% of the portfolio and ranks #338 among its holdings.

13 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

F.L. Putnam Investment Management held 288,810 shares of Exagen worth $1.34M as of Q2 2026.
Exagen was a new F.L. Putnam Investment Management position in Q2 2026.
Exagen made up 0.02% of F.L. Putnam Investment Management's portfolio in Q2 2026, its #338 holding.
13 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on F.L. Putnam Investment Management's 13F filing for Q2 2026, filed 6 Aug 2026.